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Abstract: The Wnt/CTNNB1 pathway is often deregulated in epithelial tumors. The ZFP36 gene,
encoding the mRNA binding protein Tristetraprolin (TTP), is downregulated in several cancers, where
it has been described to behave as a tumor suppressor. By this report, we show that Wnt/CTNNB1
pathway is constitutively activated, and ZFP36 expression is downregulated in Squamous Cell
Carcinoma (SCC) cell lines compared to normal keratinocytes. Moreover, we suggest that the decrease
of ZFP36 expression might depend on the activity of transcriptional repressors SNAI1, SLUG and
TWIST, whose expression is induced by Wnt/CTNNB1, highlighting a potential regulatory mechanism
underlying ZFP36 downregulation in epithelial cancers.
Keywords: ZFP36; Wnt/CTNNB1 signaling pathway; squamous cell carcinoma; transcriptional
repressors; EMT
1. Introduction
ZFP36 gene encodes the Zinc-finger RNA-binding protein Tristetraprolin (TTP). TTP expression is
induced by different stimuli, such as mitogenic agents [1] and inflammation [2,3]. TTP localizes in the
nucleus, but stimulation leads to its translocation in the cytosol where it recognizes and binds to specific
AU motifs at the 3′UTR (AREs) of its target mRNAs, thereby triggering their degradation [4,5]. Owing to
this activity, TTP is involved in the anti-inflammatory response, by targeting and inducing degradation
of several pro-inflammatory cytokines mRNAs [6], thereby preventing chronical inflammation [7].
With respect to TTP mediated RNA degradation activity, this protein works most efficiently at a
specific concentration, and it is able to self-regulate its own mRNA’s stability in order to remain
at optimal levels [8]. TTP’s role in cancer is still controversial. It is recognized as a protein that
inhibits tumor progression although, for instance, it also acts on CD8+ lymphocytes by blocking
cell-mediated antitumor immune response [9]. ZFP36 gene is frequently downregulated in different
cancers [9], where, although specific mutations affecting it are not described, it seems to act as a tumor
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suppressor [5,10,11]. In addition, TTP has been shown to be able to revert mesenchymal to epithelial
phenotype in many tumor cell lines, by down regulating the transcriptional repressors SNAI1 and
TWIST1 [6].
The skin is the largest organ in the human body. To maintain its homeostasis, it relies on
keratinocyte stem cells (KSCs), that have potential for self-renewal and differentiation [12,13]. Epithelial
differentiation is finely regulated in healthy skin, through a balance between transcription factors,
growth factors, structural molecules and enzymes [14,15]. Squamous cell carcinoma (SCC) is the second
most frequent non-melanomatous skin cancer, and it develops as a consequence of over-proliferation
of epidermal squamous cells [16]. It exists in two forms: cutaneous (cSCC) and mucosal, and originates
from mutated keratinocytes (KCs). SCC can have different levels of differentiation, different stages
of keratinization and a variable presence of intercellular bridges, depending on the characteristics
of the cells of the paving epithelium of the epidermis. This neoplasm can occur as recurrence or
de novo on irradiated or chronically damaged skin. KCs are thought to be the “Starting cells” of
squamous cell carcinoma [17]. Different cancer stem cells populations have been isolated in SCC;
these cells are controlled by the integrin/FAK and the TGF-β signaling pathways. The tyrosine kinase
FAK interacts with the Wnt/CTNNB1 signaling pathway in the regulation of the initial stages of skin
carcinogenesis [16].
Epithelial to mesenchymal transition (EMT) is a process, in which cells gradually lose the epithelial
phenotype assuming a mesenchymal one through changes in gene expression. Cells undergoing
EMT tend to lose cell-cell contacts, reshape the cytoskeleton and exponentially increase motility and
invasion capacity [18–21]. When a carcinoma begins to metastasize, cellular changes are the same as in
EMT [22]. EMT is driven by a series of transcription factors and proteins involved in Wnt/CTNNB1
pathway such as ZEB1/2, SNAI1/2 (respectively SNAI1 and SLUG) and TWIST1/2 which are activated
in the early stages of the transition [19]. Wnt/CTNNB1 signaling, is the canonical pathway of Wnt
proteins. An aberrant regulation of this pathway can cause organ fibrosis, degenerative diseases [23],
metabolic pathologies and malignancies [24]. CTNNB1 protein (95 kDa) can be divided into three
domains: N-terminal domain, armadillo domain with twelve armadillo repeats and the C-terminal
domain. Different phosphorylation events mediate CTNNB1 localization [25]. When CTNNB1 is not
phosphorylated it tends to accumulate in the cytoplasm. In the nucleus CTNNB1 recognizes and binds
the TCF/LEF complex (T Cell Factor/Lymphoid Enhancer-binding Factor), a transcription factor which
recognizes WREs (Wnt-Response-Elements) on Wnt target genes. In vitro, the transcriptional complex
is able to bind the promoter region of the E-cadherin gene, leading to its down-regulation [26,27].
Moreover TCF/LEF bound to CTNNB1 stimulates transcription of Wnt target genes, such as TWIST and
SNAI1 [28]. Consequently, Wnt/CTNNB1 pathway mediates adhesion between cells, their mobility,
and proliferation [29]. During EMT, SNAI1 and SLUG (SNAI2) induce the expression of mesenchymal
genes or repress epithelial ones by binding E-box sequences via their DNA binding domain. TWIST
proteins are bHLH (basic helix-loop-helix) transcription factors with a comparable activity [6]. TTP
is able of inhibiting EMT, by directly binding ARE sequences located in the mRNAs of TWIST1 and
SNAI1, thereby leading to their degradation [30]. By this paper, we suggest the existence of an inverse
correlation between TTP and the transcriptional repressors SNAI1, SLUG and TWIST, in that not only
they are directly targeted by TTP, but they are capable of transcriptionally repressing the expression of
the ZFP36 gene.
2. Results
2.1. Wnt/CTNNB1 Pathway Constitutive Activation and ZFP36 Down-Regulation in SCC Cell Lines
Compared to Normal Keratinocytes
CTNNB1 subcellular localization was assessed by immunofluorescence. As shown in Figure 1A(1),
in healthy keratinocytes CTNNB1 is found predominantly in cell-cell junctions and in the cytoplasmatic
membrane. In SCC cell lines (Figure 1A(2–4)), CTNNB1 shows perinuclear localization, as shown by
fluorescence signal in the cytoplasm around the cells’ nucleus. Among the three analyzed cell lines,
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perinuclear localization is observed principally in the SCC13 and SCC15 lines (Figure 1A(2) and A(3)
respectively), and less strongly in SCC12 cells (Figure 1A(4)), that display a distribution of CTNNB1
more similar to healthy keratinocytes. Figure 1B shows a western blot analysis suggesting that TTP
expression is downregulated in SCC12, SCC13 and SCC15 cell lines compared to normal keratinocytes.
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SCC12. TWIST protein is only upregulated in SCC15 cells, compared to normal keratinocytes. 
Figure 1. Immunofluorescence highlighting CTNNB1 localization and immunoblotting of ZFP36
expression. Panel (A) shows confocal microscope images of healthy keratinocytes (panel (A(1))) and
SCC12, SCC13 and SCC15 (Panels (A(2)), (A(3)) and (A(4)) r spectively). Scale bars 30 µm, 50 µm
and 100 µm. Panel (B) shows the western blot analysis of TTP expression in the three SCC cell lines
compared to normal keratinocytes. The plot below indicates the normalized densitometric analysis
of immunoblot.
2.2. Expression of SLUG, SNAI1 and TWIST in SCC12, 13 and 15 Cell Lines Compared to
Normal Keratinocytes
Figure 2 depicts a western blot analysis of the transcriptional repressors SLUG, SNAI1 and
TWIST (Figure 2A, B and C, res ctively) in three SCC cell lines compared to normal keratinocytes.
The three repressors are expressed at different levels in the three cell lines. SLUG protein is upregulated
predominantly in SCC13 and to a lesser extent in SCC15 and SCC12 cells. SNAI1 protein is induced
especially in SCC13 and SCC15 cells and is almost completely absent in SCC12. TWIST protein is
only upregulated in SCC15 cells, compared to normal keratinocytes. Overall, at least one of the three
repressors is induced in every SCC cell line compared to healthy keratinocytes.
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Figure 2. Immunoblotting of SNAI1 (Panel A), SLUG (Panel B) and TWIST (Panel C) proteins expression
in healthy keratinocytes and SCC c ll lines (29 kDa, 34 kDa 22 kDa r s ti l ). The pl t below
indicates the normalized densit metric analysis of immunoblot.
2.3. Treatment with the Wnt/CTNNB1 Inhibitor FH535 Induces ZFP36 Up-Regulation and the
Downregulation of Transcriptional Repressors SNAI1, SLUG and TWIST
Wester blot analysis was performed 48 and 72 h pon treatment with FH535 in the cell lines
SCC12, SCC13 and SCC15. F llowing FH535 treatment, the expression of CTNNB1 tends to decrease,
while ZFP36 is upregulated in the three cell lines (Figure 3A–C). Figure 4A–C show a western
blot analyzing the expression of repressors SNAI1, SLUG and TWIST in SCC12, SCC13 and SCC15
cell lines (panels A, B, C, respectively). SCC12 cells express neither SNAI1 nor TWIST. They only
show SLUG expression, which is downregulated following treatment with the FH535 inhibitor as
represented in Figure 4A. SCC13 cells show SNAI1 and SLUG expression. These two repressors are both
down-regulated following treatment with FH535 (Figure 4B). SCC13 do not show TWIST expression
(Figure 4B). Figure 4C shows the expression of the three transcriptional repressors in the SCC15 cell
line. As in the previous tumor lines, SLUG and SNAI1 are downregulated by the treatment with FH535.
Moreover, in this cell line TWIST follows the same path and it shows complete downregulation at 72 h
after treatment.
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Figure 3. CTNNB1 (96 kDa) and TTP (36 kDa) expression in SCC cell lines treated with FH535, inhibitor
of Wnt/CTNNB1 signal pathway. T0 refers to the beginning of the treatment with FH535 or DMSO,
respectively. Analysis of the treatment was performed at 48 and 72 h by estern Blot. In the panels
(A–C) show expression of CTNNB1 and TTP in SCC12, SCC13 and SCC15 respectiv ly. The plot below
indicates the normalized densitometric analysis of immunoblot.
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Figure 4. Western blot analysis of SNAI1, SLUG and TWIST expression (29 kDa, 34 kDa and 22 kDa
respectively) in SCC cell lines treated with FH535. T0 refers to the beginning of the treatment with FH535
or DMSO. Panels (A–C) show repressors’ expression following treatment in SCC12, SCC13 and SCC15
cells respectively. The plot below indicates the normalized densitometric analysis of immunoblot.
2.4. SNAI1 and SLUG Proteins Bind the ZFP36 Promoter Region Both in Healthy Keratinocytes and in SCC15
Cell Line
To characterize the ZFP36 promoter, and to verify a possible regulation of its expression by the
above mentioned transcriptional repressors, we performed an in silico analysis of 2994 base-pairs’ (bp)
genomic region upstream of the hum n ZFP36 gene. To this purpose E-box sequences (5′-CANNTG-3′),
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known binding sites for SNAI1, SLUG and TWIST proteins, were searched using MatInspector software
(Genomatix). We discovered a nearly canonical E-Box element, composed by two distinct and adjacent
5′-CANNTG-3′ sequences, located 2416 bp upstream from the most common annotated transcriptional
start site (TSS1) of ZFP36. Moreover, a TATA-box regulatory sequences was annotated 24 nt upstream
from the TSS1. A second, alternative TSS (TSS2) has been mapped 16 nt downstream from TSS1
(Figure 5A).
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 Figure 5. (A) Sequence of the genomic region located upstream of the human ZFP36 gene, and
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(5′-CANNTG-3′) were indicated in red. A canonical TATA box element was highlighted by box. Two
alternative transcriptional start sites (TSS) were indicated by black arrows. (B) Schematic representation
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primer set amplifying the ZFP36 promoter region (ZFP36 Promoter) and a negative control region
located downstream from the ZFP36 gene (ZFP36 3′CTRL). (C) Chromatin immunoprecipitations were
performed with anti-SNAI1 and anti-SLUG antibodies. CA = control antibody. Green bars represent
the binding on the ZFP36 promoter region whereas dark grey columns indicate the enrichment on its
relative control region. Data are expressed as mean percentage of total input chromatin ± SEM of at
least three independent experiments. * p-value ≤ 0.05; ** p-value ≤ 0.01; *** p-value ≤ 0.001 evaluated
with t-test.
To test whether this E-Box could indeed bind to these transcriptional repressors, we performed
chromatin immunoprecipitation assay in healthy keratinocytes and SCC15, unique among the
previously exploited squamous cancer cell lines that simultaneously expresses all the three mentioned
repressors (as shown in Figure 2). To date, both SNAI1 and SLUG proteins were found to bind
significatively to the E-Box within the ZFP36 promoter when compared to a negative control region
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located downstream to the ZFP36 gene both in human keratinocytes and in SCC15 cells (Figure 5B,C).
In addition, the binding of SLUG to the ZFP36 promoter in SCC15 cells is significantly higher than
in healthy keratinocytes although no obvious alteration in its expression was observed (Figure 2).
No significant differences were instead observed between the binding capability of SNAI1 to ZFP36
promoter in healthy keratinocytes and SCC15 cell line (Figure 5C).
Together, these data hence demonstrate that SNAI1 and SLUG repressors actually bind to ZFP36
proximal putative promoter region and hence might be involved in its transcriptional repression.
3. Discussion
Although ZFP36 expression is lost in several malignancies, the mechanisms underlying this event
are still poorly understood. Specific mutations in the promoter region of ZFP36 are not been described
so far. Epigenetic causes have been proposed [24]. However, we hypothesize that, since, in general,
loss of ZFP36 fosters tumor progression, in different cell contexts ZFP36 down-regulation might result
from the modulation of pathways that are crucial to a specific tumor. To this regard, we observed
in a previous work that ZFP36 expression in colorectal carcinoma cell lines is inversely correlated to
Wnt/CTNNB1 pathway activity [6]. Recently, it has also been suggested that miRNA-423 is capable
of promoting tumor cell proliferation and migration by enhancing Wnt/CTNNB1 activity, thereby
inducing ZFP36 down-regulation [31]. We also analyzed the activity toward ZFP36 promoter of specific
microRNAs induced by Wnt/CTNNB1, among others (microRNA29b1/a), but never get conclusive
results (data not shown). Moreover, we were able to exclude the possibility that TCF7L2/CTNNB1
transcriptional complex might directly bind ZFP36 promoter, thereby repressing its expression (data not
shown). The correlation between Wnt/CTNNB1 and ZFP36 is noteworthy and the molecular process
that links the signal transduction pathway to ZFP36 modulation deserves to be clarified. The aim of
this work is to demonstrate that the correlation existing between ZFP36 and the Wnt/CTNNB1 signal
transduction pathway is mediated by three transcriptional repressors (SNAI1, SLUG and TWIST) that
are induced by CTNNB1 pathway and that modulate ZFP36 by binding to its promoter.
The protein product of ZFP36 (TTP) is known to directly target the mRNAs encoding SNAI1,
SLUG and TWIST [6]. When Wnt/CTNNB1 signaling is deregulated, the sustained expression of
SNAI1, SLUG and TWIST is involved in the epithelial to mesenchymal transition. Since it is known
that ZFP36 is downregulated in epithelial cancer, that its down-regulation stabilizes the expression
of a set of genes involved in EMT and that restoration of its expression contributes to the rescue
of a more epithelial phenotype [6], the existence of this functional inverse correlation between TTP
and the repressors made it plausible to hypothesize that the repressors might be the link allowing
Wnt/CTNNB1 signaling to negatively regulate ZFP36 gene.
We elected to perform this study on a model of epithelial cancer and chose SCC since, to date,
there were no data on this disease and ZFP36. As we observed by immunofluorescence, Wnt/CTNNB1
is constitutively active in the cell lines SCC12, SCC13 and SCC15. Moreover, we observed that ZFP36
is down-regulated in these cells compared to healthy keratinocytes, as opposed to transcriptional
repressors SNAI1, SLUG and TWIST, that are upregulated in these SCC lines as a consequence of
Wnt/CTNNB1 constitutive activity. We observed that inhibition of Wnt/CTNNB1 via the specific
molecule FH535 determines a decrease of SNAI1, SLUG and TWIST expression and the rescue of
ZFP36 expression. Western blots throughout the paper show the presence of multiple differently
migrating bands for TTP. In our opinion these bands are specific and their different height represents
a different phosphorylation level. In fact, it is well known that TTP can be phosphorylated by p38
MAP kinase and that this event results in protein stabilization and in the loss of mRNA destabilizing
activity [32]. Moreover, as mentioned in the introduction, TTP mRNA destabilizing capability is active
at a specific protein concentration [8]. At different concentrations the protein undergoes inactivation by
phosphorylation. In our hands this makes over-expression experiments particularly tricky, since the
achievement of very high expression levels often leads to the accumulation of an inactive form of TTP.
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In order to further verify our hypothesis, we analyzed by chromatin immunoprecipitation the
ability of the transcriptional repressors SNAI1 and SLUG to bind ZFP36 promoter at specific E-boxes.
Results showed that both repressors are indeed capable of binding ZFP36 promoter and, in particular,
the binding of SLUG to the promoter is significantly higher in SCC15 cells than in healthy keratinocytes.
Results obtained on SNAI1, although statistically not significant, suggest that also this repressor
preferentially binds ZFP36 promoter in SCC15 cells compared to healthy keratinocytes. A wider
set of chromatin immunoprecipitation data is needed to confirm statistical significance. Chromatin
immunoprecipitation assays on TWIST binding are currently ongoing.
In general, we showed that in SCC, and possibly in other tumors of epithelial origin characterized
by EMT, where ZFP36 is down-regulated and the alteration of Wnt/CTNNB1 signaling plays a major
role, the link between the signal transduction pathway and ZFP36 is represented by the transcriptional
repressors described in this paper. In tumors of different origin, where Wnt/CTNNB1 signaling is not
involved and ZFP36 is down-regulated, in the absence of specific mutations or epigenetic events (that
are not to be excluded), the tumor advantage-conferring TTP silencing can be achieved as a consequence
of the deregulated activity of other specific pathways. This idea seems also acceptable considering the
fact that TTP expression is often induced physiologically in order to switch off a biological process,
be it the inflammatory response, proliferation or other. Conversely, different deregulated pathways
underlying transformation and the origin of different tumors might converge, among many other
consequences, to the inactivation of the expression of the ZFP36 gene.
4. Materials and Methods
4.1. Cell Cultures, Treatments and Transfections
SCC12, SCC13, and SCC15 cell lines were purchased from ATCC (Teddington, UK) and maintained
in SCC medium (45% DMEM, 45% Ham’s F12, 10% fetal bovine serum, 2% L-Glutammine, 1%
penicillin/streptomycin/amphotericin, 1 M HEPES, and 400 ng/mL hydrocortisone), under standard
conditions 37 ◦C, 5% CO2. Normal human keratinocytes were isolated from healthy skin biopsies
obtained from waste materials from the surgical room, after the patient’s informed consent signature,
in Policlinico di Modena - University Hospital of Modena, as previously reported [33]. They were
grown in Keratinocyte Growth Medium (KGM; Lonza, Walkersville, MD, USA).
The tumor lines were treated with FH535 (Sigma, St. Louis, Missouri, USA) dissolved in DMSO
and diluted in culture medium at the concentration of 30 µM. Control cells received the same volume
of DMSO [6].
4.2. Western Blot Analysis
Total protein extracts were obtained by lysing the cells in RIPA buffer (50 mM TRIS-HCl pH 7.4,
150 mM NaCl, 1% NP40, 1 mM sodium deoxycholate, 1 mM sodium orthovanadate, 1 mM EDTA) with
addition of Protease Inhibitor Cocktail 1x (Roche Applied Science, Penzberg, Germany). Cells were
resuspended and centrifuged in the buffer and subsequently quantified by Bradford assay. A fixed
amount of protein for each sample was loaded on SDS-Polyacrylamide gels for each sample and
transferred to a nitrocellulose membrane. The membranes were blocked with 5% non-fat milk in TBS
+ 0.1% Tween, and then immunoblotted overnight at 4 ◦C with the following primary antibodies:
Tristetraprolin (#71632, Cell Signalling Technologies, Danvers, MA, USA); TWIST1 (#46702, Cell
Signalling Technologies, Danvers, MA, USA); SLUG (#9585, Cell Signalling Technologies, Danvers, MA,
USA); SNAI1 (#3895, Cell Signalling Technologies, Danvers, MA, USA). One-hour incubation at room
temperature was enough for the primary antibody against CTNNB1 (BD Transduction Laboratories
610154, South San Francisco, California, USA). The nitrocellulose membranes were then incubated
with secondary antibodies: either Goat anti-rabbit IgG-HRP or Goat anti-mouse IgG-HRP (Santa Cruz
Biotechnology sc-2004 and sc-2005, Santa Cruz, CA, USA). Chemiluminescence was detected with
ChemiDoc (BIO-RAD, Hercules, California, USA).
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4.3. Immunofluorescence
Untreated cells were grown on slides coated with 1 mL of collagen IV and fixed with 4%
paraformaldehyde for 20 min at room temperature, then washed with PBS. Cells were permeated with
1% Triton X100 for 5 min on ice, and then incubated with Blocking Solution (Goat Serum 10% and
BSA 1% in PBS) for 20 min. The slides were incubated with the primary antibody anti-CTNNB1 (BD
Transduction Laboratories 610154) diluted 1:100 in blocking solution, overnight at 4 ◦C in humidified
chamber. Subsequently the slides were incubated for 45 min at room temperature with anti-mouse
Alexa Flour 488 antibody (Invitrogen, Carlsbad, California, USA), diluted 1:300. Fluorescent samples
were analyzed by confocal scanning laser microscope (Leica TCS SP2, Wetzlar, Germany).
4.4. Chromatin Immunoprecipitation
Chromatin immunoprecipitation assays were performed as previously described [34]. Briefly,
chromatin from human keratinocytes and human SCC15 cell line was crosslinked with 1% formaldehyde
and subjected to immunoprecipitation with 5 µg anti-SNAI1 (AF3639, R&D Systems, Minneapolis,
Minnesota, USA), 5 µg anti-SLUG (C19G7) (9598S, Cell Signalling Technologies, Danvers, MA, USA)
whereas 5 µg of normal mouse IgG (sc-2025, Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used
as control antibody (CA). The enrichment of the amplified genomic region in immunoprecipitates was
evaluated by quantitative real-time PCR (qPCR) and calculated as a percentage of total input chromatin.
Mean enrichments for each ChIP were assessed using three independent experiments. Primers used
in qPCR analysis were: ZFP36-Prom Fw_: 5′-AGGGTTTTCACTTAGGGCGA-3′; ZFP36-Prom Rev_:
5′-TTAGTCAGGCTGGTCACGAA-3′; ZFP36-3′CTRL Fw_: 5′-GCTCCTTGACCCAGCTTCGG-3′;
ZFP36-3′CTRL Rev_: 5′-ACATTCCGTCCTCCCCACCC-3′. Statistical analysis (t-test) was performed
with Prism GraphPad version 8.0, San Diego, CA, USA [34].
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writing–review and editing, T.Z.-M., C.P.; project administration, A.M. and A.G.; funding acquisition, T.Z.-M. All
authors have read and agreed to the published version of the manuscript.
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Abbreviations
ARE AU-rich element
ATCC American Type Culture Collection
bHLH basic Helix-Loop-Helix
bp base pairs
cSCC cutaneus Squamous Cell Carcinoma
CTNNB1 β-catenin
DMEM Dulbecco’s Modified Eagle Medium
DMSO Dimethyl sulfoxide
EDTA Ethylenediaminetetraacetic acid
EMT Epithelial to Mesenchymal Transition
FAK Focal Adhesion Kinase
FH535 C13H10Cl2N2O4S
Ham’s F12 Ham’s Nutrient Mixture F12
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HRP Horseradish peroxidase
KSC Keratinocyte Stem Cells
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PBS Phosphate-Buffered Saline Phosphate-Buffered Saline
PCR Polymerase Chain Reaction
RIPA Radioimmunoprecipitation Assay
SDS Sodium Dodecyl Sulfate
SEM Standard Error of the Mean
SCC Squamous Cell Carcinoma
TBST Tris-buffered saline, 0.1% Tween 20
TCF/LEF T Cell Factor/Lymphoid Enhancer-binding Factor




ZFP36 Zinc Finger Protein of 36 kDa
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